RegenPRP™ + ATS

The addition of autologous thrombin serum (ATS) to RegenPRP™ physiologically starts the coagulation process and thus enables the production of a leucocyte-reduced platelet gel.

What is Plus Technology ?

What is RegenPRP™ ?

RegenPRP™: the platelet concentrate prepared with Regen Lab technology provides an autologous reservoir of growth factors.

Platelets, in addition to their role in hemostasis, are key factors in tissue repair mechanisms.1 They provide essential growth factors, such as FGF, PDGF, TGF-β, EGF, VEGF, IGF, which are involved in stem cells migration, differentiation and proliferation. Platelet growth factors also stimulate fibroblasts and endothelial cells to induce the deposition of new extracellular matrix and neovascularisation, respectively.
Plasma contains many factors essential for cell survival including nutrients, vitamins, hormones, electrolytes, growth factors (such as IGF and HGF), and proteins. Among the plasma proteins, the molecules vital for the coagulation process and for formation of the fibrin polymer will serve as a scaffold for cell migration and new tissue generation.2
Platelet-Rich Plasma

• Proven role in the healing of tissues, with key roles in cell migration, proliferation and differentiation

• Mechanism of action comprises anti-inflammatory activity and activation of cell-signalling cascades

• Key role in the synthesis of new extracellular matrix for tissue regeneration

What is ATS ?

ATS is an autologous serum used to activate RegenPRP™ coagulation via a physiological pathway.

The serum contains the enzymes of the coagulation cascade in their active form, among them thrombin. Thrombin is the enzyme that converts soluble plasma fibrinogen to fibrin monomers which polymerise to form the clot. Addition of ATS, either alone or with a calcium solution, to RegenPRP™ triggers the coagulation process in a physiological manner.

This natural process induces the formation of a three-dimensional fibrin matrix in which the platelets are entrapped. This allows a long-lasting growth factor delivery at the treatment site and the fibrin matrix serves as a scaffold for new tissue reconstruction.

Related Content

All
Clinical Study Wound Care

PRP gel preparation

 

The coagulation process is a complex cascade of reactions that converts inactive prothrombin into thrombin. Thrombin is the enzyme that turns soluble fibrinogen into insoluble fibrin molecules that form the clot.

The addition of autologous thrombin serum (ATS) to RegenPRP physiologically starts the coagulation process and thus enables the formation of a leucocyte-reduced platelet rich gel.

If a calcium solution is added to the mix, this accelerates the process, and the fibrin structure is strengthened.

Technology advantages

————–

  • User-independent standardised preparation

  • Minimum volume of blood required

  • Safe closed-circuit system

  • Mechanical separation of PRP using a chemically inert separator gel with a single centrifugation at a relative centrifugal force of 1500 x g

  • Pharmaceutical grade solution of sodium citrate allowing a reversible anticoagulation

  • Addition of Autologous Thrombin Serum (ATS prepared with RegenATS™ device), either alone or combined with a calcium solution, allows to obtain RegenPRP™ in different jellified forms

  • Minimal learning curve and ease of use

  • Operationally and clinically efficient process

  • Facilitates and streamlines routine practice

Scientific advantages

————–

  • Demonstrated safety and efficacy

  • Evidence-based outcomes for numerous therapeutic indications

  • Large number of clinical studies, with over 200 publications

Biological advantages

————–

  • RegenPRP™standardised PRP that is leucocyte-reduced and easily reproducible

  • RegenLab® specific separator gel technology guarantees minimal variability

  • Platelet recovery > 80%

  • High platelet quality. Viable & functional platelets

  • Full plasma recovery. No loss of plasma growth factors and fibrinogen

  • Leucocyte-reduced PRP. Depletion of ~ 96% of pro-inflammatory granulocytes, leaving mainly lymphocytes and monocytes

  • Virtually no red blood cells. Depletion of ~ 99.7% of erythrocytes

Bibliography

1. Fountain, J. H. and S. L. Lappin (2019). Physiology, Platelet, StatPearls Publishing, Treasure Island (FL).

2. Mathew, J. and M. Varacallo (2019). Physiology, Blood Plasma, StatPearls Publishing, Treasure Island (FL).

T E C H N O L O G I E S

RegenPRP™
RegenPRP™-HA
RegenPRP™+ATS
RegenExtracell

Technology advantages

The technology ensures consistent PRP preparation with minimal blood, using a safe, closed system and inert separator gel after a quick 5-minute centrifugation at 1500g. It includes pharmaceutical-grade sodium citrate for reversible anticoagulation, is easy to use with minimal training, and streamlines routine clinical practice efficiently.

Biological advantages

RegenLab®'s separator gel ensures reproducible results with over 80% platelet recovery, high platelet quality, full plasma recovery, and minimal red blood cells. It produces leucocyte-reduced PRP, preserving essential growth factors and fibrinogen.

Scientific advantages

The technology's scientific advantages include demonstrated safety and efficacy, with evidence-based outcomes for various therapeutic indications. Supported by over 200 clinical studies, it has a robust foundation of research confirming its effectiveness.

Since 2003, Regen Lab SA has been committed to the development of a unique expertise for the design and manufa​cturing of high-quality medical devices, intended for cells therapies.

Company

CONTACT US

Discover innovative regenerative medicine solutions with Regen Lab – contact us today to elevate your treatments and enhance patient care!

Let’s Explore Your Options
Copyright © 2025 All rights reserved.